MétaCan
Menu
Back to cohort

Outcome of Immunosuppressive Treatment in Pregnant IBD Patients

2014· article· en· W2979243563 on OpenAlexaboutno aff
Razvan Arsenescu, Cheng Zhang, Kenneth Obi, Mohamed Naem, Violeta Arsenescu

Bibliographic record

VenueThe American Journal of Gastroenterology · 2014
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineInfliximabAdalimumabPregnancyInflammatory bowel diseaseRetrospective cohort studySurgeryCrohn's diseaseUlcerative colitisDiseaseInternal medicine

Abstract

fetched live from OpenAlex

Introduction: Inflammatory bowel diseases tend to have a milder course during pregnancy. Patients with more aggressive disease prior to conception are at higher risk of flares during pregnancy and the benefit of immunosuppression outweighs the treatment side effects. A significant number of pregnant IBD patients as well as their healthcare providers delay or unnecessarily stop therapies in these patients. Methods: We performed a retrospective study in a cohort of 17 pregnant IBD patients: 12 Crohn’s disease (CD) and 5 ulcerative colitis (UC). Disease characteristics were established based on Montreal classification, disease activity indices (Harvey Bradshaw, UC DAI), review of endoscopic, radiologic, and laboratory data. Clinical chart review was performed to assess outcome of pregnancy. Results: All patients presented with severe clinical and endoscopic disease within 6 month of their pregnancy. Three quarters of CD patients has extensive ileocolonic disease while 25% had stricturing/fistulizing disease. Eighty percent of the UC patients had severe pancolitis. Fifteen patients initiated anti-TNF therapy (8 infliximab, 2 adalimumab, 5 certolizumab) within 3-6 month of the pregnancy while 2 patients delayed treatment until the second trimester. Patients that delayed therapy continued to experience moderate-severe symptoms and required prednisone treatment prior to initiating certolizumab treatment. Both patients achieved remission following certolizumab treatment. One patient discontinued humira® during her second trimester and later developed a recurrence of fistulizing disease with peritoneal abscess and required surgical intervention. One patient on infliximab developed perianal abscess and underwent surgical drainage with complete remission. All other patients that continued therapy throughout the pregnancy remained in clinical remission. No other infectious of significant side effects were observed in this cohort of patients. One patient on infliximab has lost the pregnancy within the first trimester. All other patients had an uneventful course with regard to the fetal health. Conclusion: Biologic therapy in pregnant IBD patients is safe. Disease control before and during pregnancy results in high quality of life and improved fetal outcome. Ongoing education of both patients and providers with regard to safety of biologic therapy during pregnancy is important. Disclosure - Dr. Razvan Arsenescu Abbvie - Speakers Bureau Dr. Razvan Arsenescu UCB - Consulting fee Dr. Razvan Arsenescu MaunaKea - Consulting Fee.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.235
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicInflammatory Bowel DiseaseFrench-language works237,207